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ABSTRACT
◥
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal
cancer with a survival rate less than 5%. Multiple chemotherapeutic
drugs have been tested to improve patient prognosis; however, the
clinical efficacy of these treatments is low. One of the most con-
troversial family of drugs are the proteasome inhibitors, which have
displayed promising effects in preclinical studies, but low clinical
performance. Here, we unravel a specific transcriptomic signature
that discriminates a subgroup of patients sensitive to the protea-
some inhibitor carfilzomib.
Experimental Design: First, we identified a subpopulation of
PDAC-derived primary cells cultures (PDPCC) sensitive to the
proteasome inhibitor carfilzomib. Then, we selected a transcrip-
tomic signature that predicts carfilzomib chemosensitivity using
independent component analysis on the transcriptome of PDPCC.
Finally, we validated the signature in an independent cohort of
PDAC biopsy-derived pancreatic organoids.
Results: Sensitive phenotype was characterized by a high
expression of genes related with a cornified/squamous pathway
and a downregulation of epithelial–mesenchymal transition
genes. Interestingly, carfilzomib-sensitive transcriptomic profile
did not show any association with the proteasome activity but
strongly correlates with ATF4 and CHOP expression, which
are key markers of the unfolded protein response and critical
to trigger the cell death program. Concordantly, sensitive phe-
notype showed a high level of the de novo RNA and protein
synthesis compared with the resistant one and, most important,
cell death induced by carfilzomib is dependent of the transla-
tional activity.
Conclusions: We demonstrate the existence of a carfilzo-
mib-sensitive PDAC subgroup with a specific transcriptomic
phenotype that could explain the biological reason for this
responsiveness.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent
and lethal type of pancreatic cancer with a survival rate less than 5%,
and it is projected to become the second cause of cancer-related
death by 2030 (1, 2). This low survival is associated with late
detection and presence of metastasis at diagnosis (3, 4). The main
problem to face at the time of the diagnosis and treatment of this
disease is the high heterogeneity among patients. Heterogeneity is
related to a combination of malignant alterations at multiple levels
of tumor biology, such as genetic, epigenetic, and microenviron-
mental factors (5–7). To address this issue, several studies have
defined PDAC subtypes using transcriptomic and multi-omics data,
allowing tumor stratification and identification of potential thera-
peutic targets (8–14). However, the application of this new knowl-
edge to repurpose drugs in PDAC treatment is limited. In this
context, we predicted and demonstrated the potential use of
approved drugs, such as ezetimibe (15), bromodomain and extra-
terminal inhibitors (BETi; refs. 13, 16), E2F inhibitors (12), and
trifluoperazine (17). Following this rationale, the proteasome inhi-
bitors (PI) are a promising group of drugs to assess for treating
PDAC. PIs have shown high effect in preclinical studies both
in vitro and in vivo, but poor clinical response in PDAC (18–22).
Identifying a subgroup of PDAC sensitive to PIs and characterizing
their molecular phenotype could help in increasing their clinical
response through patient selection and by understanding the bio-
logical mechanism involved in the response.
The ubiquitin–proteasome system (UPS) is a critical factor in
maintaining cell homeostasis through the degradation of unfolded or
misfolded proteins, which ensure the cellular protein quality control,
and is responsible for the removal ofmore than 80%of them (23, 24). A
central component of the UPS is the proteasome 26S, which is
composed by a 19S regulatory particle and a 20S core particle; the
core particle contains three beta proteolytic subunits that mediate
the protein degradation. A protein substrate for the UPS is marked
with a polyubiquitin chain, which is recognized by the 19S protea-
some subunit and then is translocated into the 20S proteolytic
chamber for degradation (24–27). Disruption of UPS results in
growth arrest and apoptosis-related to the activation of unfolded
protein response (UPR).
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Usually, cancer cells that have shown an elevated protein syn-
thesis activity display a strong dependency on proteasome function
because this process overloads the capacity of the endoplasmic
reticulum to mediate protein folding (20, 24, 25, 28). Bortezomib,
carfilzomib, and ixazomib PIs have been developed and approved
for clinical use against multiple myeloma and mantle cell lympho-
ma. However, their efficacy in solid tumors is limited, probably due
to their heterogeneity (20, 29).
Several studies have defined predictive markers of PIs sensitivity
mainly in myeloma and breast cancer. These studies reported that
the expression levels of antiapoptotic genes, such as MCL1 (30, 31)
or the UPR capacity (32–35), are critical factors to determinate the
PIs sensitivity. Despite the biological implications highlighted by
these works, they do not show enough clinical efficiency.
In this work, we identified a specific transcriptomic signature
that discriminates a subgroup of patients sensitive to carfilzomib
using 20 PDAC-derived primary cell cultures (PDPCC), which
was validated on 14 commercially available cell lines (CACL), and
an independent cohort of biopsy-derived pancreatic organoids
(BDPO). Moreover, the carfilzomib sensitivity was not correlated
with the proteasome activity but showed an association with protein
synthesis and UPR response.
Materials and Methods
PDAC samples and cell culture
The PDAC samples used in this work were obtained from
three expert clinical centers after receiving ethics review board
approval. Patients were included in this project under the PaCaO-
mics clinical trial (number 2011-A01439-32). Consent forms of
informed patients were collected and registered in a central data-
base. The studies were conducted in accordance with the Declara-
tion of Helsinki.
Twenty PDPCCs were used in this study, thirteen as training
cohort, and seven as validation cohort. These PDPCCs were
obtained as described previously (15, 36). Patients’ clinical data
are detailed in Supplementary Tables S1 and S2. Briefly, PDAC
samples were subcutaneously implanted in nude mice obtaining
patient-derived xenografts (PDX). When PDXs reached 1 cm of
diameter they were split into several small pieces (1 mm3) and
processed in a biosafety chamber. After a fine mincing, they were
treated with collagenase type V (C9263; Sigma-Aldrich, Inc.) and
trypsin/EDTA (25200-056; Gibco, Sigma-Aldrich, Inc.) and sus-
pended in DMEM supplemented with 1% w/w penicillin/strepto-
mycin (Gibco, Life Technologies) and 10% of FBS (Lonza). After
centrifugation, cells were resuspended in serum-free ductal media
(SFDM) adapted from Schreiber and colleagues (14) and conserved
at 37C in a 5% CO2 incubator.
PDPCC sensitivity to proteasome inhibitors
Three thousand cells per well were seeded in 96-well plates in
SFDM. Twenty-four hours later, the media were supplemented
with increasing concentrations of BZT (Selleckchem), carfilzomib
(Selleckchem), or ixazomib (Selleckchem) and incubated for 72 hours.
Cell viability wasmeasured with PrestoBlue (Thermo Fisher Scientific)
reagent and quantified using the plate reader Tristar LB941 (Berthold
Technologies). Each experiment was repeated at least three times.
Eight increasing concentrations of PIs were used ranging from 0 to
5,950 nmol/L. Valueswere normalized and expressed as the percentage
of the control (vehicle), which represents the 100% of normalized
fluorescence.
Proteasome activity and proteasome inhibition assay
PDPCCs were cultured in SFDM and plated during 24 hours
before starting the experiment at 10,000 cells per well in a 96-well
plate. Proteasome activity was assessed by adding specific substrates
(chymotrypsin-, trypsin-, and caspase-like), in the presence of
luciferase using the Proteasome-Glo assay reagents according to
the manufacturer's instructions. For the proteasome inhibition
assay, PDPCCs were preincubated with PIs for 2 hours at 100 and
2,000 nmol/L. After, medium with PIs was removed and the
proteasome activities were measured. Luminescence was detected
using the plate read Tristar LB941 (Berthold Technologies), and
values were normalized with the total cell viability measured by
Presto Blue (Thermo Fisher Scientific).
PDPCC RNA extraction and RNA-seq analysis
PDPCC total RNA was extracted using RNeasy Mini Kit (Qiagen).
RNA libraries were prepared (Illumina TruSeq RNA v2) and run on
the Illumina High Seq-2000 for 101 bp paired end reads. Gene
expression profiles were obtained using the MAP-RSeq v.1.2.1 work-
flow (37). MAP-RSeq consists of alignment with TopHat 2.0.626
against the human hg19 genome build and gene counts with the
HTSeq software 0.5.3p9 (38) using gene annotation files obtained from
Illumina. Gene counts were normalized using upper quartile. mRNA
sequencing data are available under accession number EMBL-EBI:
E-MTAB-5039.
Transcriptomic signature generation and differential gene
expression analysis
Carfilzomib chemosensitivity signature was extracted using inde-
pendent component analysis (ICA), which discriminates the biological
relevant components from the transcriptome. ICA components were
calculated on the PDPCC 10,000 most variant genes applying the
JADE algorithm in MineICA R package (39). Pearson correlation was
used to identify the component with the higher/significant association
with carfilzomib chemosensitivity measured as base ten logarithm of
Translational Relevance
Pancreatic ductal adenocarcinoma (PDAC) low survival and
minimal benefit of the current treatments have been associatedwith
the high heterogeneity of this disease. Patient stratification and
selection is a key factor to improve clinical outcomes. Proteasome
inhibitors are a family of drugs with a high potential for PDAC
treatment. However, their clinical results are variable. Transcrip-
tomic data from PDAC-derived patient cell lines and organoids
were used to generate and validate a signature that predicts the
chemosensitivity to carfilzomib, a second-generation proteasome
inhibitor. Interestingly, carfilzomib-sensitive phenotype is charac-
terized for a squamous profile with a high capacity of unfolded
protein response (UPR) induction, mediated for ATF4 and
CHOP, and high translational levels. In contrast, the resistant
phenotype expresses increased levels of epithelial–mesenchymal
transition genes and a low UPR induction capacity. Altogether,
these results provide a transcriptomic signature to use an FDA-
approved drug for the treatment of patients with PDAC and
potentially improve their clinical outcome. Furthermore, they
validate the use of transcriptomics data from patient-derived
models for the study of low frequency and lethal cancers.
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IC50. The final signature was built with the genes that explain≥3 SDs of
the selected component distribution. To further confirm the gene
profile associated with carfilzomib chemosensitivity, differential gene
expression using EdgeR R package was performed on the PDPCC
training cohort. Differential expressed genes (DEG) were extracted
according to a log2 fold change ≥2 and an FDR < 0.05.
Functional analysis
To characterize the pathways related to the selected ICA compo-
nent, a gene set enrichment analysis (GSEA) was performed using
fgsea R package (40), which implements GSEA on a preranked list of
genes and MsigDB signaling database (41). Pearson correlation was
used to rank the genes according to the level of association among the
ICA sample contribution matrix and the genes applied to extract the
components. In addition, GSEA on DEGs was done through gene
ontology (GO) analysis and pathway analysis on Reactome databases
using the R packages, ClusterProfiler and ReactomePA, respectively.
Cell line microarray and chemosensitivity data analysis
CEL microarray files for 21 pancreatic cancer CACL were down-
loaded from ArrayExpress database (E-MTAB-3610). Microarray
data were processed following the workflow detailed in the maEnd-
ToEnd R package. Briefly, oligo R package was used to read and
perform background subtraction and normalization of probe set
intensity applied by the Robust Multi-array Analysis (RMA). Then,
common cell lines with the Dependency Map chemosensitivity
database (DepMap) were used (n ¼ 14) for carfilzomib chemosen-
sitivity signature validation. For each cell line, effective concentra-
tion 50 (EC50) was extracted from PRISM Repurposing Secondary
Screen 19Q4 database.
Transcriptomic subtype classification and carfilzomib signature
association
The Moffitt–Purist classification was applied to normalized data
using the published weights for each gene (13). A centroid classifier
approach was used for Chan-Seng-Yue (14), Collisson (9), and
Bailey (8) subtype classification. Centroid was calculated using
K-means on ICGC RNA-seq database (PACA-AU), previous sam-
ple selection according to the expression profile of each subtype
measured by hierarchical clustering on principal components from
FactoMineR R package. After that, the subtypes were predicted for
the new datasets using the “cl_predict” function from clue R
package. To measure the association with a specific transcriptomic
subtype, Pearson correlation coefficients were calculated among
the normalized counts of the genes used for the classification and
the contribution of each sample to the signature in the training
cohort.
De novo in-cell RNA and protein synthesis
Initially, 5,000 cells/well were seeded in 8-well m-slides (BD Bio-
sciences) and incubated for 24 hours before treatment. Then, the cells
were treated with the vehicle or carfilzomib 100 nmol/L for 3 and
6 hours. To determine the nascent ARN and protein, CuAA Cell
Reaction Buffer Kit was used (Jena Bioscience). Nascent protein and
RNAwere marked for its detection with an alkyne containing ethynyl-
labeled uridine or O-propargyl-puromycin (OP) probe, respectively.
Detection is based on a click reaction with a fluorescent azide. The
reaction was conducted according to the manufacturer's instructions.
Reaction visualization and image acquisition were done at 20 and
40 with a Nikon eclipse 90i microscope (Nikon), and the fluorescent
intensity was quantified by NIH Image J software (42).
De novo protein synthesis inhibition
To evaluate the impact of PDPCC's protein translation on the
chemosensitivity against carfilzomib, 3,000 cells/well were plated
in a 96-well plate 24 hours before the start of the experiment. The
protein synthesiswas inhibitedwith 4mg/mLof puromycin for 2 hours.
After that, the cells were cultured with vehicle and carfilzomib at two
concentrations, 2,000 and 5,000 nmol/L for 24 hours. Cell viability was
measured with PrestoBlue (Thermo Fisher Scientific) reagent quan-
tified using the plate reader Tristar LB941 (Berthold Technologies).
Values were normalized and expressed as the percentage of the control.
Protein extraction and Western blot analysis
To perform protein expression analysis, the cells were treated
during 3 and 6 hours with vehicle or 100 nmol/L of carfilzomib. Then,
the cells were detached and homogenized in RIPA buffer. The proteins
were separated by SDS-PAGE (29:1 acrylamide:bis-acrylamide, Euro-
medex Laboratories) in 10% to 12% running gel and 4% stacking gel,
in an electrophoresis cell. Proteins were electrotransferred to a nitro-
cellulose membrane (Immobilon-P, EMD Millipore Corporation)
at 250 mA for 2 hours. To identify proteins, the membranes were
blocked for 1 hour at room temperature with 5% powdered milk in
PBS containing 0.1% Tween 20. Next, they were incubated overnight
at 4C with the rabbit polyclonal antibodies anti-ATF4 (1:1,000;
Cell Signaling Technology), anti-ATF6 (1:2,000; Cell Signaling Tech-
nology), and the goat polyclonal antibody anti-CHOP (1:1,000; Cell
Signaling Technology). For the immunoreaction, themembranes were
incubated with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1:3,000 dilution, Suther Biotech) orHRP-conjugated rabbit
anti-goat IgG (1:3,000 dilution, Suther Biotech). The outcome was
visualized using the Chemiluminescent HRP substrates (Millipore
Corporation) for chemiluminescence development. To normalize the
results, monoclonal anti-b-tubulin (1:6,000 dilution, Sigma-Aldrich,
Inc.) was used on the same membranes and revealed with HRP-
conjugated goat anti-mouse IgG (1:3,000 dilution, Suther Biotech).
The membranes were scanned using a PXi multi-application imager
(Sygene). The estimation of bands was performed using a prestained
protein ladder (SeeBlue Plus2, ThermoFisher Scientific) as amolecular
weight marker. The intensity of each protein band was quantitated
using the NIH Image J software (42), and the results were expressed as
the optical density of each protein/optical density of b-tubulin.
Immunofluorescence and nuclear localization quantification
Five thousand cells/well were seeded in 8-well m-slides (BD Bio-
sciences) and incubated 24 hours before treatment. The cells were
treatedwith the vehicle or carfilzomib at a concentration of 100 nmol/L
for 3 and 6 hours. After that, the medium was removed, and the cells
were fixed with cold methanol for 15 minutes at 4C. Previous to the
incubation with the primary antibodies, cells were washed twice with
PBS andwith blocking serum solution (Vector Laboratories) diluted in
1.5% PBST for 30 minutes. Then, the cells were incubated with the
primary antibody overnight at 4C. The primary antibodies used were
rabbit polyclonal anti-ATF4 (1:100 Cell Signaling Biotechnology),
anti-ATF6 (1:200 Cell Signaling Biotechnology), and goat anti-
CHOP (1:100; Cell Signaling Biotechnology). The secondary anti-
bodies used were Alexa 488–conjugated anti-rabbit (1:400; Invitrogen,
Thermo Fisher Scientific) and Alexa 488–conjugated anti-goat (1:400;
Thermo Fisher Scientific), which were incubated with the sections for
60 minutes at room temperature. The slides were counterstained with
mounting medium for fluorescence with DAPI (H-1,200; Vector
Laboratories). Negative controls were processed in the same manner
with omission of the primary antibodies. One hundred cells were
Fraunhoffer et al.
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selected randomly to quantify the nuclear signal of ATF6, ATF4, and
CHOP. Imageswere captured using an opticalmicroscope (Eclipse 90i;
Nikon) with an attached digital camera (DXM1200C; Nikon).
UPR genes signature analysis
The gene sets for UPR (M5922), ATF6 (M27284), PERK (M2781),
ATF4 (M796), and CHOP (M1477) were extracted from MsigDB
signaling database (41). The normalized, gene-wise zero-centering,
and unit variance scaling gene counts were plotted according to the
resistant and sensitive phenotype in the training cohort. In addition,
Pearson correlation coefficients were calculated among the normalized
counts of the genes that compose the ATF6, PERK, ATF4, and CHOP
gene sets and the contribution of each sample to the signature.
Biopsy-derived pancreatic organoid generation, RNA
extraction, and RNA-seq analysis
BDPOs were obtained from 22 consecutive endoscopic ultra-
sound-guided fine-needle aspirations (EUS-FNA) from patients
with PDAC. Briefly, PDAC cells were obtained from the biopsies
through slight digestion with the Tumor Dissociation Kit (Miltenyi
Biotec) at 37C for 5 minutes. Isolated cells were placed into 12-well
plates coated with 150 mL growth factor–reduced Matrigel (Corn-
ing) and cultured with advanced DMEM/F12 supplemented with
HEPES (10 mmol/L; Thermo Fisher Scientific), human recombi-
nant FGF10 (100 ng/m; PeproTech), human recombinant EGF
(50 ng/mL; PeproTech), human recombinant Noggin (100 ng/mL;
Bio-Techne), human Gastrin 1 (10 nmol/L; Sigma-Aldrich, Inc.),
Nicotinamide (10 mmol/L; Sigma-Aldrich, Inc.), N-acetylcysteine
(1.25 mmol/L; Sigma-Aldrich, Inc.), B27 (Thermo Fisher Scientific),
A83-01 (500 nmol/L; Bio-Techne), and Y27632 (10.5 mmol/L; Bio-
Techne). The plates were incubated at 37C in a 5% CO2 incubator,
and the media changed every 3 to 4 days. Total RNA was extracted
using RNeasy Mini Kit and RNA libraries were prepared as
described above. Gene expression profiles were obtained using the
MAP-RSeq v.1.2.1 workflow as described above. Gene counts were
normalized using upper quartile.
Signature projection
The signature projection on PDPCC, CACL, and BDPO transcrip-
tome was performed using the MASS R package (43). A score that
classifies PDPCC, CACL, and BDPO according to the degree of
chemosensitivity was calculated applying the cross-product among
theMoore–Penrose generalized inverse of the gene contribution to the
signature and the RNA expression matrix.
BDPO carfilzomib chemosensitivity
BDPOs were disaggregated with accutase (Thermo Fisher Scientif-
ic), and 1,000 cells/well were plated in a 96-well round bottom ultra-
low plate (Corning) with the medium described above. Twenty-four
hours later, the media was supplemented with increasing concentra-
tions of carfilzomib (Selleckchem) and incubated for 72 hours. Cell
viability was measured with CellTiter-Glo 3D (Promega) reagent
quantified using the plate reader Tristar LB941 (Berthold Technolo-
gies). Each experiment was repeated at least three times. Eight increas-
ing concentrations of PIs were used ranging from 0 to 5,950 nmol/L.
Values were normalized and expressed as the percentage of the control
(vehicle), which represent 100% of normalized fluorescence.
Time-lapse analysis
To validate the carfilzomib chemosensitivity on BDPOs, we
performed 72-hour time-lapse video microscopy on one carfilzo-
mib-sensitive (PDAC104T) and one resistant BDPO (PDAC109T)
with 10 and 2,000 nmol/L of carfilzomib. Cell viability was mea-
sured using two dyes: IncuCyte NucLight Rapid Red for living cells
(Sartorius) and IncuCyte Cytotox green reagent for death cells
(Sartorius). Celldiscoverer 7 microscope (Zeiss) was used for image
acquisition and the fluorescent intensity was quantified by NIH
Image J software (42). Fluorescent values were normalized and
expressed as the percentage of the control.
Statistical analysis
The inhibitory concentration 50 (IC50) values, AUC, logarithm base
10 transformation for IC50, EC50, and Bartlett test for sphericity were
performed in Prism 8.3 (GraphPad). Pearson correlation coefficients
and the significance levels were calculated using the Hmist R package.
Mann–Whitney test and Kruskal–Wallis test were performed with R
basic functions. Correlograms and the heatmaps were built with
ggplot2 and ComplexHeatmap R packages (44, 45), respectively.
Results
Characterization of PDPCC PIs sensitivity
An in vitro cytotoxic assay was performed in 13 PDPCCs with 3
different PIs (carfilzomib, bortezomib, and ixazomib) to analyze their
differential sensitivity. The clinical characteristics of patients from
where PDPCCswere derived are displayed in Supplementary Table S1.
PDPCCs showed a different pattern of sensitivity to PIs (Fig. 1A)
measured by IC50 and AUC (Supplementary Table S1). However,
Pearson correlation coefficient was significantly high for bortezomib
and ixazomib for both logIC50 (r¼ 0.66; P¼ 0.01; Fig. 1B) and logAUC
(r¼ 0.62;P¼ 0.01;Fig. 1B), whereas carfilzomib did not correlate with
the other PIs.
To stratify PDPCCs with respect to PI sensitivity, we analyzed
whether the logIC50 or the log-AUC captures the variability observed
in the chemograms. Variability evaluated by Bartlett test showed that
logIC50 was the parameter that better characterized the variability
among PIs (P < 0.0001; Fig. 1C). Thus, we used logIC50 to stratify the
PDPCC according to PI sensitivity. Stratification was performed by
grouping the logIC50 for the three PIs establishing one SD as a
threshold to determine the most and less responsive groups. Carfilzo-
mib was the only drug that showed a discriminative pattern of
sensitivity among PDPCCs with 23% (n ¼ 3) and 77% (n ¼ 10)
classified as sensitive and resistant, respectively (Supplementary
Table S1; Fig. 1C).
Deriving a transcriptomic signature to predict carfilzomib
sensitivity
A specific transcriptomic phenotype associated to carfilzomib
sensitivity was detected using ICA decomposition on a set of 12
transcriptomes derived from the previous chemosensitivity evaluation
(Fig. 1C). The ICA algorithm was applied on the 10,000 most variant
genes and the presence of five components (ICA1-ICA5) was revealed.
ICA1 and ICA3 showed a strong association with patients’ age
(Fig. 2A). ICA4 was the only component that correlated significantly
with carfilzomib logIC50 (r ¼ 0.69; P ¼ 0.013; Fig. 2A). Ninety-five
genes that explain ≥3 SDs of ICA4 were selected to constitute
carfilzomib chemosensitivity signature (Supplementary Table S2).
Applying unsupervised K-means clustering on the signature revealed
two PDPCC subgroups with a specific gene profile (Fig. 2B). Carfil-
zomib-sensitive PDPCCs were enriched in keratins (KRT), kallikreins
(KLK), and small proline-rich proteins (SPRR), whereas the resistant
subgroup showed a higher expression of VIM, CDH2, and POSTN
Carfilzomib in PDAC
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(Fig. 2B; Supplementary Table S2). Pathway analysis showed that the
sensitive PDPCCs have increased levels of genes related with a
cornified/squamous phenotype (NES ¼ 2.63; FDR ¼ 0.01; Fig. 2C),
associated with a downregulation of epithelial–mesenchymal transi-
tion (EMT) genes (NES ¼ 2.09; FDR ¼ 0.03; Fig. 2C). These
observations were confirmed through differential expression analysis
with the detection of 358 DEGs, which were related with cornification
(GO:0001533; FDR ¼ 0.02) and keratinization pathways (R-HSA-
6805567; FDR < 0.0001), detected by GO and Reactome pathway
analysis, respectively (Supplementary Fig. S1; Supplementary
Table S3). Although the signature is enriched in genes/pathways
related to a basal/squamous subtype, it was not detected in a statistical
association with this phenotype or another across the different
transcriptomic classifications (Supplementary Fig. S1F).
Figure 1.
Characterization of chemosensitivity profile after proteasome inhibitors treatment in PDPCC. A, Chemosensitivity analysis of the proteasome inhibitors carfilzomib,
bortezomib, and ixazomib on 13 PDPCC. B, Correlation between bortezomib and ixazomib measured with Pearson correlation showed a high correlation among
bortezomib and ixazomib, both logIC50 (r¼0.66; P¼0.01) and logAUC (r¼0.62; P¼0.01), while carfilzomib did not correlate with the other inhibitors.C, LogIC50 is
the chemosensitivity parameter that characterizes the variability among theproteasome inhibitors usingBartlett test (P<0.0001). Chemogramsandboxplots fromA
and C, respectively, are plotted as the mean  SD.  , P < 0.05.
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Carfilzomib chemosensitivity signature was validated in 7 addition-
al PDPCCs, and an external cohort of 14 CACL in which tran-
scriptomes (Supplementary Table S1; Supplementary Table S2)
were projected on ICA4 component to calculate a chemosensitivity
score (Supplementary Fig. S2). Both PDCC and CACL projected
scores highly correlate with the logIC50 (r ¼ 0.84; P ¼ 0.01;
Supplementary Fig. S2A) and logEC50 (r ¼ 0.76; P ¼ 0.002;
Supplementary Fig. S2B), respectively. Altogether, these results
confirm the presence of a PDAC subgroup sensitive to carfilzomib,
which is not related to a specific subtype.
Proteasome activity and chemosensitivity to PIs in PDPCCs
The reduction of proteasome activity and PI resistance have
been associated with a pro-mesenchymal phenotype (27, 46).
Figure 2.
Carfilzomib chemosensitivity signa-
ture identification. A, ICA on 12 PDPCC
RNA-seq. ICA4 is the component with
the highest correlation with carfilzo-
mib logIC50 (r ¼ 0.69; P ¼ 0.013). B,
Ninety-five genes explained more than
3 times the variability to carfilzomib
sensitivity among PDPCC and dis-
played a clear phenotypic discrimina-
tion among the resistant and sensitive
subgroups. Boxplots describe the dif-
ference in total gene expression mea-
sured as the logarithm base 2 of
counts per million among resistant
and sensitive PDPCC. C, GSEA analysis
revealed that the sensitive PDPCC are
enriched in genes associated with a
cornified/squamous phenotype (NES
¼ 2.63; FDR ¼ 0.01) and a reduction
in epithelial–mesenchymal transition
genes (NES ¼ 2.09; FDR ¼ 0.03).
Boxplots are plotted as the median
and the extremes represent the
first and third quartile, respectively.
 , P < 0.05 (Mann–Whitney test).
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Interestingly, the carfilzomib sensitivity PDPCC subgroup showed a
strong downregulation of EMT genes. Thus, to evaluate the asso-
ciation between proteasome activity and carfilzomib chemosensi-
tivity, we measured chymotrypsin-, trypsin-, and caspase-like activ-
ity in PDPCCs (Fig. 3A). Chymotrypsin-like was the main activity
detected (61.07%  10.17%), whereas trypsin-like was the lowest
(12.77%  4.40%). Next, we analyzed the association among PIs’
sensitivity and the proteasome activities using Pearson correlation.
Only bortezomib correlated marginally with the proteasome activ-
ities (Fig. 3A), indicating that the proteasome activity
is not a critical modulator of carfilzomib sensitivity. To
further analyze the differential impact of carfilzomib on proteasome
Figure 3.
Proteasome activity before and after treatment of PDPCC. A, Proteasome activities were measured in the training PDPCC group and correlated with the logIC50 of
bortezomib, carfilzomib, and ixazomib. B, Proteasome activity inhibition was evaluated in four PDPCC, two resistant (PDAC087T and PDAC056T) and two sensitive
(PDAC089T, and PDAC084T) at two concentrations (100 and 2,000 nmol/L) for carfilzomib, bortezomib, and ixazomib. Bar plots in A represent the proteasome
normalized by cell viability and the pie plots show the relativeproteasomeactivity (RPA) as proportion of the totalmeasured activity. Bar plots inB are represented as
percentage in relation to the control (vehicle).  , P < 0.05.
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activity related to the chemosensitivity phenotypes, two carfilzomib-
sensitive (PDAC089T and PDAC084T) and two carfilzomib-resistant
(PDAC087T and PDAC056T) PDPCCswere treatedwith the three PIs
at two concentrations, 100 and 2,000 nmol/L, for 2 hours, and after
that, proteasome activities were measured (Fig. 3B). As we expected,
all PIs showed a potent inhibition of chymotrypsin-like activity even at
100 nmol/L with the highest effect on the sensitive PDPCCs. The
caspase-like activity was negatively modulated by the three PIs inde-
pendently of the phenotype, whereas trypsin-like was affected for
carfilzomib at 100 nmol/L only. These results suggest that the pan-
inhibition of the carfilzomib on the three proteasome activities
could explain the presence of a specific PDPCC subgroup with a high
sensitivity to this PI.
UPR activity response correlates with carfilzomib
chemosensitivity phenotype
Previous studies have shown induction of UPR as a mechanism
of chemosensitivity to PI treatment in pancreatic cancer cell lines
(17, 35, 47, 48). We expanded these studies examining UPR
response in two resistant (PDAC056T and PDAC087T) and two
sensitive (PDAC084T and PDAC089T) PDPCCs with two carfil-
zomib concentrations (50 and 100 nmol/L) at 3 and 6 hours. The
resistant PDPCCs showed a low capacity of UPR response (Fig. 4;
Supplementary Fig. S3). Carfilzomib-resistant phenotype was relat-
ed with high levels of the endoplasmic reticulum (ER) chaperone
GRP78 and a reduced induction of UPR-related transcriptional
factors ATF6, ATF4, and CHOP in the presence of carfilzomib
(Fig. 4A and B; Supplementary Fig. S3A). Following the rationale,
we quantify the nuclear localization of the study UPR-related
transcriptional factors at 100 nmol/L of carfilzomib at 3 and 6 hours
(Fig. 4C). Despite this, ATF6 protein expression increased in the
sensitive PDPCCs at 6 hours; the nuclear ATF6 was higher in the
resistant PDPCCs with 75%  2% of positive nuclei, whereas the
sensitive PDPCCs showed a peak at 3 hours with a cytoplasmatic
accumulation of ATF6 at 6 hours. Contrarily, nuclear localization
for ATF4 was lower in the resistant PDPCC than the sensitive
one at 6 hours. CHOP followed ATF4 pattern with 83%  1% of
positive nuclei in the sensitive PDPCCs. To further understand the
mechanism associated with the differential UPR response among
carfilzomib-resistant and -sensitive subgroups, the expression levels
of the gene sets of UPR, ATF6, PERK/ATF4, and CHOP extracted
from MsigDB signaling database were analyzed. Globally, the UPR
gene set did not show statistical differences among subgroups (P ¼
0.420; Supplementary Fig. S3B). However, genes related to ATF6
(Supplementary Fig. S3C), PERK/ATF4 (Supplementary Fig. S3D),
and CHOP (Supplementary Fig. S3E) showed statistical differences.
Specifically, high levels of chaperones (HSP90B1 and HSP5/GRP78)
were observed in the resistant subgroup. In contrast, the expression
of genes related to RNA processing (EXOSC proteins) and trans-
lational regulation (PPP1R15A/GADD34) was increased in the
sensitive subgroup. Pearson correlation confirmed these observa-
tions among the expression of UPR-related genes and the carfilzo-
mib ICA4 score (Supplementary Table S3). These results suggest
that the carfilzomib chemosensitivity phenotype revealed by the
ICA analysis is related to a differential UPR response pattern and
ER stress–induced apoptosis in PDPCCs.
De novo RNA and protein synthesis in PDPCC
Protein synthesis levels play a critical role in PI sensitivity and UPR
induction (48, 49); due to this fact, we examined the levels of de novo
RNA and protein synthesis basally and after 100 nmol/L carfilzomib
treatment at 3 and 6 hours. The levels of RNA and protein synthesis
were higher in the sensitive PDPCCs than resistant PDPCCs with an
increase of 54% (P¼ 0.002) and 89% (P< 0.0001), respectively (Fig. 5A
and B). Interestingly, carfilzomib treatment did not significantly
modify the RNA or protein synthesis at either 3 or 6 hours
(Fig. 5A and B). To further confirm the effect of protein synthesis
on carfilzomib chemosensitivity, we inhibited protein translation with
4 mg/mL of puromycin and measured cell viability after carfilzomib
treatment at 2,000 and 5,000 nmol/L. Sensitive PDPCCs treated with
puromycin showed a significant increase in the cell viability both at
2,000 and 5,000 nmol/L (Fig. 5C).
Validation of carfilzomib chemosensitivity in BDPOs
Twenty PDAC patient BDPOswere used to confirm the carfilzomib
chemosensitivity signature extracted from the PDPCCs. Initially, the
BDPO transcriptomes were projected on the carfilzomib signature
applying the ICA4 component (Supplementary Table S2). Then, six
BDPOs were selected to test their carfilzomib sensitivity. Clinical data
are available in Supplementary Table S1. A high correlation was
observed between the carfilzomib sensitivity pattern and the projected
ICA4 score (r¼0.92; P¼ 0.01; Fig. 6). The three BDPOs classified as
sensitive showed a lower IC50 and AUC than the BDPOs scored as
resistant (Fig. 6A and B). In addition, cell viability was measured in a
72-hour time-lapse video microscopy. As expected, a strong response
to carfilzomib was observed in the BDPOs scored as sensitive
(PDAC104T) with an almost complete reduction of the cell viability
at 48 hours posttreatment even at 10 nmol/L (Fig. 6C; Supplementary
Video S1). Contrarily, the organoid scored as resistant (PDAC109T)
showed a cell viability near to 100% at the end of the experiment
(Fig. 6D; Supplementary Video S2). All these results confirmed the
reliability of the signature to predict the PDAC sensitivity to
carfilzomib.
Discussion
Despite being an overall dismal cancer, the clinical outcome of
pancreatic adenocarcinoma is difficult to anticipate principally due
to the huge heterogeneity that this tumor presents. An accurate
predictive method applicable for all patients would greatly improve
individual care by identifying the most appropriate course of
treatment. In fact, RNA has an unrecognized and extensive poten-
tial for personalized clinical management of patients with cancer.
Indeed, the molecular classification of pancreatic adenocarcinoma
is still a highly debated subject, with broad discordances between
subtyping systems. High-throughput data have contributed to
generate a novel classification and identify new cellular and molec-
ular biomarkers in PDAC (6, 8–15). However, specific chemosen-
sitivity signatures that predict the response to clinically approved
drugs are poorly characterized. Several studies have proved a strong
correlation among PDAC transcriptional profile, drug response,
and clinical survival (15, 36, 50). In this work, we identify a
subgroup of PDAC sensitive to carfilzomib and unravel a tran-
scriptomic predictive signature identifying them.
PDAC sensitivity to bortezomib has been characterized exten-
sively, even at a clinical level, with poor and uncertain results, which
have been related with low drug penetration, mutations, or over-
expression of b5 subunit and the presence of multidrug efflux
transporters (18, 19, 23, 25, 29, 50, 51). This lack of clear results
has set aside the other PIs as PDAC therapeutic drugs. Using a panel
of 13 PDPCCs, we characterized an in vitro chemosensitivity profile
for the three FDA-approved PIs. The general sensitivity among the
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Figure 4.
UPR correlateswith carfilzomib chemosensitivity signature.A,Western blot analysis of GRP78, ATF6, ATF4, and CHOP comparing their expression among a resistant
(PDAC056T) and sensitive (PDAC084T) PDPCC after carfilzomib treatment (50 and 100 nmol/L) at two time points, 3 and 6 hours. B,Western blot quantification
comparing PDPCC resistant and sensitive subgroups. C, Immunofluorescence of ATF6, ATF4, and CHOP and quantification of nuclear signal comparing resistant
and sensitive PDPCC. Scale bar, 50 mm. Bar plots in B are plotted as themean SD. ns, no significance; RE, relative expression.  , P < 0.05;  , P < 0.01;  , P < 0.001;
 , P < 0.0001 (Mann–Whitney test).
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Figure 5.
De novo RNA and protein synthesis in relation to carfilzomib chemosensitivity phenotype. A and B show the RNA and protein synthesis measured for a click
reaction with a fluorescent azide. C, Inhibition of protein synthesis with puromycin rescue the sensitive PDPCC after 24 hours of treatment with 2,000 and
5,000 nmol/L of carfilzomib. Scale bar, 50 mm. Bar plots in A and B are plotted as the mean  SD. 5-EU, ethynyl-labeled uridine; ns, no significance; OP, O-
propargyl-puromycin.  , P < 0.05;  , P < 0.01;  , P < 0.001; , P < 0.0001 (Mann–Whitney test).
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Figure 6.
Validation of carfilzomib chemosensitivity signature using BDPO.A andB,BDPO transcriptomeswere projected on ICA4 to calculate a chemosensitivity score which
were validated with an in vitro chemosensitivity assay. C and D, BDPO chemosensitivity profile was confirmed by a time-lapse experiment with a sensitive
(PDAC104T) and resistant (PDAC109T) BDPO for 72 hours at two concentrations (10 and 2,000 nmol/L). E, BDPO logIC50 correlates significantly with the projected
ICA4 score (r ¼ 0.92; P ¼ 0.01). Scatter plot are plotted as the mean  SD and normalized in relation to the control (vehicle).
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three inhibitors was markedly different across the PDPCCs. Car-
filzomib and bortezomib showed the lowest IC50, whereas ixazo-
mib's cytotoxic activity was observed at higher concentrations.
However, the variability in the sensitivity was lower with bortezo-
mib and ixazomib than carfilzomib. As we expected, most of
PDPCCs fell as intermediate responders for all the PIs, while
carfilzomib was the only PI defining a significantly sensitive PDAC
subgroup.
Transcriptomic analysis using the ICA algorithm demonstrated
the existence of a gene signature that discriminates carfilzomib-
sensitive and -resistant subgroups without being associated with a
specific transcriptomic subtype. This chemosensitivity-predictive
signature is composed of 95 genes that correlate with the PDPCC
EMT status. Sensitive cells are enriched in epithelial-associated
genes such as KRTs, KLKs, and SPRRs, whereas resistant PDPCCs
showed a pro-mesenchymal profile. These observations are consis-
tent with previous studies that have observed that the PI resistance
is associated with the EMT induction capacity and the differenti-
ation state (46). However, our results contrast with Genovese
and colleagues, who, using a SMARCB1 deficient subpopulation
of mice pancreatic cancer–derived cells, observed an association
among an increase in mesenchymal markers and a high sensitivity
to PI (52). These might be explained due to the fact that Genovese
and colleagues performed their analysis in a particular subpopula-
tion of tumoral cells derived from senescence escaper clones,
which do not recapitulate the real phenotypic heterogeneity of
human pancreatic cancer, in which multiple cell populations with
different phenotypes and EMT status could coexist (14), whereas
the carfilzomib chemosensitivity signature was identified and val-
idated using the global transcriptomic heterogeneity gradient with-
out pointing out a specific cell subpopulation. Thus, the carfilzo-
mib-sensitive phenotype could be related to a differentiation degree,
which is not transcriptomic subtype dependent and has low EMT
induction capacity. In contrast with other types of solid tumors that
have displayed a strong correlation among PI sensitivity
and proteasome activity (20, 24, 52), PDPCC sensitivity to carfil-
zomib did not correlate with proteasome activity. However, carfil-
zomib was the only PI that targeted the trypsin-like activity, a factor
that has been postulated as central for the use of PIs in solid
tumors (53, 54).
PIs affect the cancer cells in multiple ways, such as NF-kB
inactivation and cell-cycle arrest (20, 25, 26, 29). However, UPR
is crucial to trigger the cellular events that culminate with the
activation of the cell death program. PIs promote severe ER stress,
associated with ATF4 expression, which leads to the transcription of
CHOP, a transcriptional factor that induces proapoptotic protein
(48, 49). Here, we demonstrated that the carfilzomib-sensitive
PDPCCs have a higher UPR induction capacity than the resistant
ones. Moreover, this differential sensitivity to carfilzomib treatment
correlates positively with the nuclear levels of both ATF4 and
CHOP and the genes associated with their pathways. Contrarily,
ATF6 and chaperones, such as HSP90B1 and HSP5/GRP78, were
highly expressed in the resistant PDPCCs. These results suggest that
the PDAC-sensitive profile could be explained by the absence of an
ER stress compensatory mechanism mediated by ATF6 and GRP78,
and a lowest UPR threshold. The same pattern of sensitivity has
been observed in multiple myeloma cells, and it was explained by
the translational levels, where the PI-responsive tumors showed
increased levels of protein synthesis (35). Following these observa-
tions, we measured the levels of transcription and protein synthesis
in the PDPCCs before and after treatment. We detected that the
sensitive cells have increased protein and RNA synthesis levels in
comparison with the resistant PDPCCs, even after carfilzomib
treatment. Also, we demonstrated that protein synthesis
is critical in the carfilzomib sensitivity because translational inhi-
bition protects the sensitive PDPCCs from cell death. The high
levels of protein synthesis in a context of increased ATF4, which is
related to translational suppression through eIF-2a phosphoryla-
tion, could be explained by the induction of PPP1R15A/GADD34,
which promotes eIF-2a dephosphorylation and translational acti-
vation (55, 56). Finally, to further confirm the transcriptomic
signature applicability to predict the carfilzomib chemosensitivity,
BDPOs were used because it is a model that preserves
some characteristics of the original tumor as differentiation and
the ability to form 3 dimensional glands preserving the muco-
secretory phenotype particularly in differentiated tumors. As
expected, BDPOs showed a similar chemosensitivity compared with
PDPCCs with a strong response in the sensitive BDPOs even at low
carfilzomib concentration.
In summary, this is the first study to identify a transcriptomic
stratification of PDAC based on the sensitivity to carfilzomib and
to propose a putative molecular mechanism explaining the differ-
ential sensitivity. Furthermore, this finding contributes to the
application of a personalized approach for the treatment of pan-
creatic cancer, associated with the capacity to identify the excep-
tional responsive patients independently of histologic or molecular
classification, which could not characterize with enough accuracy
the tumoral variability and consequently propose a therapeutic
approach. Finally, here we confirm the possibility of using tran-
scriptomic data to the repurposing of FDA-approved drugs for
pancreatic cancer.
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